BTIG reiterates a Buy rating on Establishment Labs (ESTA) with a $62 price target following a transfer of coverage. The firm views the Motiva breast implant as a “disruptive technology” that is likely to replace current implants given its “unique appearance, natural feel and impressive safety profile.” The industry has experienced relatively minimal design innovation and discouraging adverse event rates over many years, the analyst tells investors in a research note. BTIG believes Motivab s 40%-plus share in its more established markets is indicative of Establishment’s potential to capture share from entrenched players in newer markets such as the U.S. and China.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Buy Rating for Establishment Labs Holdings: Easing Trade Tensions and Product Launches Drive Growth Prospects
- Establishment Labs upgraded to Buy from Hold at Needham
- Establishment Labs’ Earnings Call: Mixed Sentiments and Optimistic Outlook
- Establishment Labs Reports Q1 2025 Financial Results
- Establishment Labs Holdings: Strong Market Performance and Promising Growth Drive Buy Rating